Cord blood stem cell therapy - Kangstem Biotech

Drug Profile

Cord blood stem cell therapy - Kangstem Biotech


Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kangstem Holdings
  • Developer Kangstem Biotech
  • Class Antirheumatics; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I/II Crohn's disease
  • Phase I Plaque psoriasis
  • No development reported Rheumatoid arthritis
  • Discontinued Amyotrophic lateral sclerosis; Cancer; Diabetes mellitus; Niemann-Pick diseases; Pain; Retinal disorders

Most Recent Events

  • 17 Jan 2018 Phase-I clinical trials in Plaque psoriasis in South Korea (SC) (NCT02918123)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in South Korea (Parenteral, Injection)
  • 11 Nov 2016 Efficacy and adverse events data from a phase I trial for Rheumatoid arthritis were presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top